Clinical Trial Update: An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

View source ↗

Summary

Brensocatib has received marketing approval for Non-Cystic Fibrosis Bronchiectasis. The update is from an expanded-access study sponsored by Insmed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-cystic Fibrosis Bronchiectasis

Drugs mentioned

• Brensocatib (brensocatib)

Snippet

Sponsor: Insmed Incorporated | Conditions: Non-Cystic Fibrosis Bronchiectasis | Status: APPROVED_FOR_MARKETING